secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2026-06-17T11:35:15+00:00
Accession:  0001818794-26-000003
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics expands Hercules debt facility to $400M, borrows $50M on June 16, 2026
--------------------------------------------------------------------------------

- Expanded loan facility to aggregate $400M with two new $50M tranches and increased final tranche by $25M.
- Borrowed $50M on closing; outstanding principal now $200M; up to $200M additional available ($125M milestone-based, $75M discretionary).
- Minimum cash covenant reduced to 40% of outstanding obligations (from 60%), tested only if market cap < $1.65B; testing starts July 1, 2027.
- Interest rate: WSJ prime + 2.45% (floor 7.50%); interest-only period through July 1, 2029, extendable to maturity.
- Maturity date July 1, 2030; first-priority security interest on substantially all assets including IP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000181879426000003/0001818794-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000181879426000003/dyn-20260616.htm
  HTML page:      https://secwatch.observer/filing/0001818794-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer